Explore 3 Stock Ideas & Industry Insights Download Free Report
The company announced a feasibility agreement to test whether targeted lipid nanoparticles can deliver its CAR-encoding messenger RNA to human T cells. The work explores a possible route towards an in vivo therapy. This is a laboratory evaluation, while the existing early-stage clinical programme …
ImmuPharma remains a development-stage biotechnology story where investors monitor clinical progress, licensing opportunities, regulatory milestones and cash runway. No specific new announcement for 19 October was verified.
• Key focus: Clinical development priorities, licensing prospects and cash runway.
IXICO plc operates in AI-enabled medical imaging analytics for neurological clinical trials.
IXICO Plc (LSE:IXI) sits in the healthcare category, with exposure to digital analytics and imaging services for neurological clinical trials.
• Oxford BioDynamics Plc (LSE:OBD) is being assessed against its next operational and financial milestones.
Proteome Sciences plc (LSE:PRM) sits in the healthcare category, with exposure to proteomics services and biomarker research supporting drug development.
Physiomics Plc (LSE:PYC) sits in the healthcare category, with exposure to mathematical modelling and simulation services for drug development.
SkinBioTherapeutics plc operates in skin microbiome science and skin-health products.
ValiRx PLC (LSE:VAL) sits in the healthcare category, with exposure to biotechnology research and early-stage therapeutic development.
We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.
These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.
We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.
These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.
Please wait processing your request...
You are not subscribed for this report, Want to See?
One of our sales representative will contact you soon!
Welcome to Kalkine!
Download Free Report
Hi! How can we help you today?
Loading…